BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells

Blood

Volumn 87, Issue 3, 1996, Pages 1113-1122

  Roger, Rémi ^b   Issaad, Cherifa ^b   Pallardy, Marc ^b   Léglise, Marie Chantal ^b   Turhan, Ali G ^b   Bertoglio, Jacques ^b   Bréard, Jacqueline ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; HYBRID PROTEIN; TUMOR NECROSIS FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; CELL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; HUMAN; HUMAN CELL; KINETICS; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0030065141     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.1113.bloodjournal8731113     Document Type: Article

References (61)

1. Martz E, Howell DM: CTL: Virus control cells first and cytolyric cells second? DNA fragmentation, apoptosis and the prelytic halt hypothesis. Immunol Today 10:79, 1989
2. Duke RC, Cohen JJ, Chervenak R: Differences in target cell DNA fragmentation induced by mouse cytotoxic T lymphocytes and natural killer cells. J Immunol 137:1442, 1986
3. Christiaansen JE, Sears DW: Lack of lymphocyte-induced DNA fragmemtation in human targets during lysis represents a species-specific difference between human and murine cells. Proc Natl Acad Sci USA 82:4482, 1985
4. Howell DM, Martz E: The degree of CTL-induced DNA fragmentation is not determined by the human vs mouse origin of the target cell. J Immunol 138:3695, 1987
5. Brahmi Z, Tomita A, Hommel-Berrey G, Woodard G, Morse P: Mouse targets undergo double-strand DNA fragmentation when exposed to syngeneic or xenogeneic LAK cells whereas human targets undergo single-strand breaks. Nat Immun Cell Growth Regul 10:196, 1991
6. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsaa staining. Nature 243:290, 1973
7. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
8. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr-abl hybrid gene. Science 233:212, 1986
9. McWhirter JR, Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/ abl fusion proteins. Mol Cell Biol 11:1553, 1991
10. Koeffler PH, Golde D. Chronic myelogenous leukemia-New concepts. N Engl J Med 303:347, 1981
11. Evans CA, Owen-Lynch P, Whetton AD, Dive C: Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in haematopoietic cells. Cancer Res 53:1735, 1993
12. Laneuville P, Timm M, Hudson AT: Bcr/abl expression in 32D cI3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res 54:1360, 1994
13. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038, 1994
14. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR/ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
15. Chang MP, Bramhall J, Graves S, Bonavida B, Wisnieski BJ: Internucleosomal DNA cleavage precedes diphteria toxin-induced cytolysis. J Biol Chem 264:15261, 1989
16. Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, Okada M, Sato Y, Wada H, Yawata Y, Suda T, Miura Y: Establishment and characterization of a human leukemic cell line with megakaryocytic features: Dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3 or erythropoietin for growth and survival. Cancer Res 51:341, 1991
17. Issaad C, Vainchenker W, Villeval JL, Varet B, Turhan AG: Retrovirus-mediated BCR-ABL (P210) gene transfer into the pluripotent human hematopoietic cell line UT-7 induces growth factor independence and erythroid differentiation. Blood 84:138a, 1994 (suppl 1)
18. Vitté-Mony I, Stancou R, Bertoglio J: Functional consequences of c-AMP accumumation in human natural killer cells. Implications for IL-2 and IL-4 signal transduction. J Immunol 145:4272, 1990
19. Russel JH, Dobos CB: Mechanisms of immune lysis. II. CTL-induced nuclear disintegration of the target begins within minutes of cell contact. J Immunol 125:1256, 1980
20. McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y. Mogil RJ, Nishioka WK, Green DG. The end of the (cell) line: Methods for the study of apoptosis in vitro, in Schwartz LM, Osborne BA (eds): Methods in Cell Biology, vol 46, "Cell Death." San Diego, CA, Academic, 1995, p 43
21. Duke RC, Cohen JJ: Quantitation of apoptotic index and cell viability using fluorescent dyes, in Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds): Current Protocols in Immunology, vol 1, suppl 3-17. New York, NY, Wiley, 1991, p 1
22. Duke RC, Chervenak R, Cohen JJ: Endogenous endonuclease-induces DNA fragmentation. An early event in cell-mediated cytolysis. Proc Natl Acad Sci USA 80:6361, 1983
23. Duke RC, Cohen JJ: The role of nuclear damage in lysis of target cells by cytotoxic T lymphocytes, in Podack ER (ed): Cytolytic Lymphocytes and Complement: Effectors of the Immune System. Boca Raton, FL, CRC, 1988, p 35
24. Russell JH: Internal disintegration model of cytotoxic lymphocyte-induced target damage. Immunol Rev 72:97, 1983
25. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J: Functional consequences of Apo-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17:51, 1995
26. +-independent T cell-mediated cytotoxicity. J Exp Med 177:195, 1993
27. Kägi D, Vignaux F, Lederman B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
28. Lowin B, Hahne M, Mattmamn C, Tshopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650, 1994
29. Trinchien G: International disintegration model of cytotoxic lymphocyte-induced target damage. Immunol Rev 72:97, 1983
30. Robertson M, Ritz J: Biology and clinical relevance of human natural killer cells. Blood 76:2421, 1990
31. Ostergaard HL, Clark WR: Evidence for multiple lytic pathways used by cytotoxic T lymphocytes. J Immunol 143:2120, 1989
32. Ostergaard HL, Kane KP, Mescher MF, Clark WR: Cytotoxic T lymphocyte mediated lysis without release of serine esterase. Nature 330:71, 1987
33. Odake S, Kam C-M, Narasimhan L, Poe M, Blake JT, Krahenbuhl OK, Tschopp J, Powers JC: Human and murine cytotoxic T lymphocyte serine proteases: Subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 30:2217, 1991
34. Hudig D, Allison NJ, Pickett TM, Winkler U, Kam C, Powers JC: The function of lymphocytes proteases. Inhibition and restoration of granule-mediated lysis with isocoumarin serine protease inhibitors. J Immunol 147:1360, 1991
35. Su B, Bochan MR, Hanna WL, Froelich CJ, Brahmi Z: Human granzyme B is essential for DNA fragmentation of susceptible target cells. Eur J Immunol 24:2073, 1994
36. Cohen GM, Sun X-M, Snowden RT, Dinsdale D, Skilleter DN: Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 286:331, 1992
37. Walker PR, Weaver VM, Lach B, LeBlanc J, Sikorska M: Endonuclease activities associated with high molecular weight and internucleosomal DNA fragmentation in apoptosis. Exp Cell Res 213:100, 1994
38. Cohen GM, Sun X-M, Fearnhead H, MacFarlane M, Brown DG, Snowden RT, Dinsdale D: Formation of large molecular weight fragments of DNA is a key commited step of apoptosis in thymocytes. J Immunol 153:507, 1994
39. Russell JH, Masakowski V, Rucinsky T, Phillips G: Mechanisms of immune lysis. III Characterization of the nature and kinetics of the cytotoxic T lymphocyte-induced nuclear lesion in the target. J Immunol 128:2087, 1982
40. Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE: Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 17:1045, 1993
41. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yasaki Y, Hirai H: Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79:2378, 1992
42. Vaux DL, Aguila HL, Weissman IL: Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing Int Immunol 4:821, 1992
43. Chiu VK, Walsh CM, Liu C-C, Reed JC, Clark WR: Bcl-2 blocks degranulation but not fas-based cytotoxicity. J Immunol 154:2023, 1995
44. Taylor MK, Cohen JJ: Cell-mediated cytotoxicity. Curr Opin Immunol 4:338, 1992
45. Apasov S, Redegeld F, Sitkovsky M: Cell-mediated cytotoxicity: Contact and secreted factors. Curr Opin Immunol 5:404, 1993
46. Hudig D, Ewolt GR, Woodard SL: Proteases and lymphocyte cytotoxic killing mechanisms. Curr Opin Immunol 5:90, 1993
47. Fuchs EJ, Bedi A, Jones RJ, Hess AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 55:463, 1995
48. Jones J, Hallett MB, Morgan BP: Reversible cell damage by T-cell perforins. Biochem J 267:303, 1990
49. Vaux DL, Haecker G, Strasser A: An evolutionary perspective on apoptosis. Cell 76:777, 1994
50. Shi L, Kraut RP, Aebersold R, Greenberg AH: A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 175:553, 1992
51. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76:977, 1994
52. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175, 1993
53. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: BCR-ABL oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764, 1994
54. Arends MJ, McGregor AH, Toft NJ, Brown EJH, Wyllie AH: Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 68:1127, 1993
55. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD: Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 21:1460, 1993
56. Gotoh A, Mityazawa K, Ohyashihi K, Toyama K: Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidulinositol 3′-kinase: Leukemia 8:115, 1994
57. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 330:820, 1994
58. Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle D, Gravett P, Franklin IM, Bandini G, Ricci P, Tura S, Iacone A, Torlontano G, Heit W, Champlin R, Gale RP: Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: Importance of a graft-versus-leukaemia effect. Br J Haematol 69:239, 1988
59. Van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman J: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocytes transfusions before the onset of hematological relapse. Blood 83:3377, 1994
60. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly R, Keever CA: Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250, 1990
61. Soiffer R, Murray C, Ritz J: Effects of low dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone-marrow transplantation. Blood 84:964, 1994